Articles tagged with Liver Tumors
Radiofrequency ablation treatment destroys cancer locally, extending life for colon cancer patients. Average survival rate after RFA is 91% at one year, 66% at two years, and 41% at three years.
Researchers at Washington University in St. Louis have developed gold nanocages that selectively accumulate in tumors and convert laser light to heat, killing malignant cells. The treatment avoids warm surrounding tissue, making it a promising approach for cancer therapy.
The US medical community has developed new transplant criteria for patients with liver cancer, aiming to ensure equitable organ allocation. The guidelines prioritize candidates based on tumor size, alpha-fetoprotein levels, and MELD scores, while also considering locoregional therapy and down-staging.
Researchers found that sorafenib therapy can reduce large kidney tumors by up to 40% prior to surgery, making patient recovery less challenging. The study's results suggest a promising new treatment option for patients with advanced kidney cancer.
Researchers at Duke University Medical Center have devised a way to deliver the right therapy directly to tumors using special molecules called aptamers. A tumor-targeting RNA aptamer was found to specifically bind to RNA helicase p68 in colorectal tumors, offering a promising approach for cancer treatment and therapy delivery.
Adding cetuximab to neoadjuvant chemotherapy significantly increases tumor response rates, making more patients eligible for potentially curative surgery. The treatment also improves the proportion of tumors deemed resectable, with a notable increase after treatment.
A consortium led by UT Health Science Center at Houston is establishing a center to conduct innovative cancer research, focusing on transport oncophysics and targeting liver cancers. Researchers aim to develop new approaches to studying cancer processes and exploiting its weaknesses to mount decisive attacks against metastatic disease.
UCI researchers developed a new approach using liposomes and peptides to precisely target cancer treatments to specific cells and organs. The study demonstrated effective delivery of doxorubicin to the liver with minimal uptake by other organs, offering a promising solution to reduce side effects.
Research finds sequential use of transarterial chemoembolization (TACE) and percutaneous cryosurgery can treat more HCC patients, even those with larger tumors. This minimally invasive technique improves patient survival times and reduces surgical complications.
A study found that S-adenosylmethionine (SAMe) prevents the formation of hepatocellular carcinoma (HCC) in rats, with a 1cm tumor reduced in size after treatment. However, high doses were not sufficient to treat established HCC cases, as the liver compensates for SAMe accumulation by metabolizing it.
A new hybrid Linac-MR system has been developed to integrate medical linear accelerators and magnetic resonance imagers for treating certain types of cancer. The system promises to help doctors monitor moving tumors in real-time during radiation treatment, improving precision and reducing damage to surrounding healthy tissue.
Researchers at Max Delbrück Center for Molecular Medicine have identified 115 genes associated with metastatic potential in colorectal cancer. The study found that BAMBI gene is more active in metastatic tumors, promoting metastasis formation through key signaling pathways.
Scientists have found that replacing microRNAs in liver cancer cells can be lethal, while leaving healthy cells unaffected. The study used a special delivery virus to introduce the microRNA into mice with liver cancer, resulting in rapid death of tumor cells.
A waste disposal protein called p62 is responsible for disposing of damaged proteins in cells, preventing the accumulation of toxic waste that can promote cancer tumor growth. Researchers discovered that controlling p62 levels can stimulate autophagy and lead to tumor suppression.
Gold nanorods can detect and treat tumors by absorbing near-infrared light, heating them up to kill cancer cells, while minimizing damage to surrounding tissues. The technology has shown promise in studies using mice, where tumors disappeared within 15 days of treatment.
The study identified GP130 somatic activating mutations in 65% of inflammatory hepatocellular tumours, revealing a new pathway of tumourigenesis. These mutations also enabled the refinement of molecular classification of hepatocellular tumors.
Researchers found SIRT1 curbs cell division by speeding up the destruction of the tumor promoter c-Myc, a key finding that may aid cancer treatment. This study supports previous research suggesting SIRT1's anti-cancer effects while also identifying its role in regulating c-Myc levels.
Researchers found that liver cancers linked to metabolic syndrome have distinct characteristics, including non-fibrotic development and better differentiation. The study suggests that the metabolic syndrome itself may cause cancer through insulin, lipid peroxidation or oxidative stress effects.
A new review of randomized controlled trials has found that radiofrequency ablation significantly improves patient survival compared to percutaneous ethanol injection. Radiofrequency treatment offered a greater survival benefit due to improved local tumor response and more predictable tumor ablation.
A new study identifies Capn4 as a key molecule associated with liver cancer recurrence and metastasis after liver transplantation. The findings suggest that Capn4 expression is correlated with clinical outcomes and could be used as a prognostic marker for diagnosis.
Researchers developed peptide-guided hollow gold spheres that target and penetrate melanoma cells, then kill them when exposed to near-infrared light. The nanospheres achieve an 8-fold increase in tumor destruction compared to untargeted nanoparticles, demonstrating potential for minimally invasive cancer treatment.
Researchers used PHIFU with short duty cycle and high intensity combined with ultrasound contrast agent (UCA) to damage rabbit liver VX2 tumour by non-thermal effect. The study found that PHIFU combination with UCA can enhance non-thermal effects of ultrasound, promoting tumor cell apoptosis and inhibiting proliferation.
A new set of criteria, called Up-to-seven, has been identified to help select patients with hepatocellular carcinoma (HCC) who can benefit from liver transplantation. The criteria assess the size and number of tumors, and suggest that some patients who previously did not meet the Milan criteria may still be good candidates for transplant.
Researchers found that reduced expressions of E-cadherin and P120 were associated with tumor grade and patient survival in cholangiocarcinoma. These biomarkers may serve as potential diagnostic and prognostic indicators for ICCs.
Research isolated a subset of pancreatic cancer cells expressing CD44 and CD24, which exhibit lower proliferative index and faster tumor growth rate. Further purification is needed to understand their biological behaviors.
Researchers developed a novel technique for detecting tumor lymphangiogenesis in rabbits, using percutaneous hepatic injection of ultrasound contrast material. The method combines percutaneous transhepatic lymphosonography (PTL) with contrast-enhanced ultrasonographic imaging to improve diagnostic ability for liver cancer.
A new study suggests that down-staging hepatocellular carcinoma can improve post-transplant outcomes for patients who undergo treatment. The research found that tumors with more favorable biology respond well to treatment and do well after liver transplantation.
Scientists have discovered a molecular marker, RIP140, that controls both metabolic processes and inflammatory responses in liver cells of mice with cancer. By switching off this molecule, the lipid balance of the liver normalized within a few days, suggesting its role in causing fatty liver in affected patients.
A recent study has cast doubt on CD133's status as a colon cancer stem cell marker, finding that the protein is expressed by most cells in colon tumors, not just stem cells. Both CD133+ and CD133- cells can initiate tumors when transplanted into mice.
A new delivery technique using skin flaps and gene therapy reduces tumor volume by 79% in rats. The treatment allows for the production of therapeutic proteins directly at the tumor site, avoiding liver damage caused by traditional intravenous administration.
A new case report presents an interesting diagnosis of IPN-B with histopathological findings and emphasizes the importance of cholangiography in diagnosing bile duct dilatation. The patient's liver specimens showed intraductal papillary proliferation, fibrovascular cores, and carcinoma in situ.
Researchers have found that increasing SULF2 expression enhances cancer cell growth and migration, while decreasing it reduces both. The study suggests that blocking SULF2 may lead to an effective treatment for liver cancer and potentially other types of cancer.
A randomized controlled trial found that combining TACE and RFA therapies resulted in longer survival times for patients with large liver cancer tumors. The therapy improved survival by slowing tumor progression and blocking the blood supply to the tumor.
Researchers have shown that MRI can non-invasively characterize brain tumors and determine which are responsive to specific treatments based on their molecular properties. The study identified five distinct MRI features linked with particular gene expression patterns, including those associated with tumor proliferation and growth.
The EORTC Intergroup trial found that chemotherapy plus surgery on liver tumors improved progression-free survival by 26% in patients with colorectal cancer. Patients who received chemotherapy before and after surgery had a higher rate of progression-free survival compared to those who underwent surgery alone.
Researchers at UT Southwestern Medical Center have found that arsenic linked to a cancer-homing drug provides a powerful imaging agent for detecting hard-to-find tumors. The technique allows physicians to detect early tumor deposits and monitor cancer's response to therapy with clear images.
A new clinical trial at Thomas Jefferson University aims to test the effectiveness of radioembolization using radiation-emitting beads in treating advanced liver cancer. The treatment, which blocks blood supply and emits targeted radiation, has shown promise in shrinking tumors and improving patient survival.
Researchers at Duke University developed a high-energy form of ultrasound imaging that produces clearer images of liver tumors. The Acoustic Radiation Force Impulse (ARFI) method uses sound waves to push on tissues, capturing their elasticity and stiffness, which can help distinguish between hard and soft tumors.
Researchers found a connection between TRAIL's receptor and cancer susceptibility, as well as inflammation and cancer via TRAIL. Mouse models with TRAIL receptor knock-out developed larger tumors after exposure to carcinogens or radiation.
A study found massive necrosis after trans-catheter treatment for liver cancer to be more common when a tumor capsule is present. Patients with tumors between 2-6 cm, low CLIP scores, and no constitutional syndrome were most likely to experience this outcome.
Researchers at the University of Texas M. D. Anderson Cancer Center and Rice University have successfully destroyed liver cancer tumors using radio waves that heat up carbon nanotubes embedded in them. While there were some side effects on healthy tissue, the study shows promise for a new therapy.
African American women are diagnosed with breast cancer at a younger age and have larger tumors than Caucasian women. The study found higher relapse rates in African American patients after treatment.
Researchers at Mayo Clinic Jacksonville have found that tiny radioactive spheres can effectively treat cancer that has spread to the liver, halting tumor growth in 71% of patients. The treatment works by delivering radiation directly to tumors using millions of tiny polymer beads containing yttrium-90.
Patients with non-cirrhotic and nontumoral extrahepatic portal vein obstruction often present with well-tolerated bleeding. Cirrhosis- and tumor-related portal vein thrombosis generally carries a grim prognosis. A large sample size study found that hypercoagulable states are less common in this population.
Researchers found significant IL-8 up-regulation in all inflammatory, non-malignant, and malignant colorectal entities compared to normal tissues. The study suggests an association between IL-8 expression and the development of colorectal cancer and liver metastases.
A recent study shows multiple-electrode radiofrequency ablation is a safe and effective way to treat large liver tumors, with 34 of 38 tumors treated in just one session. The new procedure reduces treatment time by approximately 54% compared to single-electrode systems.
Researchers discuss future directions in neuroblastoma treatment, including new approaches for high-risk patients and the development of an international classification system. Current regimens and prognosis are also analyzed, highlighting the need for improved understanding of genomic alterations to guide therapy.
A research team led by UC San Diego radiologist Michael Kuo has developed tools that can translate CT images of cancer tumors into molecular details, revealing a strong connection between imaging features and genetic activity patterns. The study found consistent associations between 75% of genes in liver tumors and imaging traits.
Researchers at Mayo Clinic have found that cryoablation is an effective treatment option for patients who are not good candidates for surgery due to size or location of the tumor. The procedure involves freezing the tumor with argon gas, resulting in short-term success in over 90% of selected patients.
Researchers at MIT have created nanoparticles that mimic blood platelets to target cancer tumors. These particles can be used for non-invasive imaging of fast-growing cancer hot spots in tumors, as well as delivering chemotherapy directly into the tumor.
Researchers successfully reactivate p53 in mice, causing tumors to self-destruct through senescence and apoptosis. This breakthrough offers potential new strategies for cancer treatment.
Researchers developed nanoparticles that home in on tumors by mimicking the clotting action of platelets, blocking up to 20% of tumor blood vessels. This system enables self-amplification of tumor targeting, leading to enhanced imaging and therapeutic delivery.
Researchers have discovered that oxidative stress contributes to neurodegeneration in a Drosophila model of Alzheimer's disease. Additionally, they found that IFN-gamma stimulates osteoclast formation and bone loss, while targeting FoxM1 may limit liver cancer progression.
Research shows pro-vitamin E, alpha-tocopheryl succinate, reduces tumour volume in experimental animals with high HER2 levels. The compound induces controlled cell death and has the potential to be an effective treatment for hard-to-treat breast cancers.
A new study shows that shaped-beam radiosurgery can treat the smallest lung tumors, allowing patients to live disease-free for years. Researchers found that 91% of treated tumors never progressed and 25% of patients were cancer-free after three years.
Scientists have developed a method to predict whether melanoma of the eye will spread to the liver, where it quickly turns deadly. The molecular screening test can detect both whether a tumor is likely to spread and how fast.
Researchers found that patients with hepatocellular carcinoma who responded well to transarterial chemoembolization (TACE) prior to liver transplantation had a higher survival rate. The study's findings challenge the traditional use of Milan criteria, which rely on tumor size and number, as a reliable predictor of recurrence.
A Chinese man's use of Longdan Xieganwan led to the development of bladder tumors and eventual kidney failure. The herb contains aristolochic acid, which has been linked to an increased risk of bladder cancer. Doctors highlight the dangers of unregulated herbal therapy and emphasize the need for regulation.
Researchers at Cold Spring Harbor Laboratory have identified two human genes, Yap and cIAP1, that contribute to liver cancer. The study reveals these proteins are overexpressed in both mouse and human tumors, suggesting they could be targeted for novel cancer therapies.
A team of researchers from Munich discovered a cellular mechanism that protects against tumours by controlling the Bcl-3 oncogene. The study identified Cyld as a potential tumour suppressor, which can accumulate around the nucleus and prevent Bcl-3 from entering it.